Castleview Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Castleview Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$409K	Buy	2,594 +992	+62%	+$157K	0.18%	136
2026 Q2	$254K	Buy	+1,602	New	+$217K	0.11%	184
2025 Q1	–	Sell	-270	Closed	-$24.7K	–	581
2024 Q4	$24.7K	Sell	270 -3,449	-93%	-$334K	0.01%	439
2024 Q3	$367K	Buy	3,719 +231	+7%	+$22.7K	0.21%	116
2024 Q2	$323K	Buy	3,488 +1,538	+79%	+$138K	0.18%	126
2024 Q1	$185K	Buy	1,950 +1,839	+1,657%	+$171K	0.1%	187
2023 Q4	$9.9K	Hold	111	–	–	0.01%	514
2023 Q3	$8.1K	Hold	111	–	–	0.01%	439
2023 Q2	$9.24K	Hold	111	–	–	0.01%	444
2023 Q1	$8.46K	Hold	111	–	–	0.01%	447
2022 Q4	$9.21K	Hold	111	–	–	0.01%	379
2022 Q3	$9K	Sell	111 -7,715	-99%	-$650K	0.01%	404
2022 Q2	$326K	Buy	7,826 +7,715	+6,950%	+$579K	0.26%	88
2022 Q1	$9K	Buy	+111	New	+$10.2K	0.01%	512
2021 Q2	$15K	Buy	+111	New	+$14.6K	0.01%	610

Other funds holding XBI

PSP Research Newtown Square, Pennsylvania $146M AUM 39.94% 1-Year Est. Return

Annex Advisory Services Brookfield, Wisconsin $6.11B AUM 13.75% 1-Year Est. Return

MIRAE ASSET SECURITIES (USA) INC. New York $3.57B AUM 26.72% 1-Year Est. Return

SGH

Sivik Global Healthcare Greenwich, Connecticut $175M AUM 28.78% 1-Year Est. Return

Parkway Wealth Management Plano, Texas $869M AUM 25.74% 1-Year Est. Return

Weatherly Asset Management Del Mar, California $1.42B AUM 33.31% 1-Year Est. Return

L. Roy Papp & Associates Phoenix, Arizona $981M AUM 26.21% 1-Year Est. Return

Royal Fund Management Lady Lake, Florida $1.26B AUM 23.83% 1-Year Est. Return

Edge Wealth Management New York $666M AUM 17.64% 1-Year Est. Return

Lake Hills Wealth Management Austin, Texas $218M AUM 31.66% 1-Year Est. Return

Castleview Partners's XBI Position: Q3 2026 in Review

Castleview Partners increased its State Street SPDR S&P Biotech ETF (XBI) stake by 62% in Q3 2026, buying an estimated $157K and bringing the position to 2,594 shares worth $409K. The position accounts for 0.18% of the portfolio, ranked #136.

Castleview Partners first reported a position in XBI in Q2 2021 and has held it in 15 quarters since. 235 funds tracked by Wall St. Rank hold XBI as of Q3 2026.

Castleview Partners held 2,594 shares of State Street SPDR S&P Biotech ETF worth $409K as of Q3 2026.
Castleview Partners bought 992 State Street SPDR S&P Biotech ETF shares in Q3 2026, an estimated $157K.
State Street SPDR S&P Biotech ETF made up 0.18% of Castleview Partners's portfolio in Q3 2026, its #136 holding.
Castleview Partners first reported a position in State Street SPDR S&P Biotech ETF in Q2 2021 and has held it in 15 quarters since.
235 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2026.

Based on Castleview Partners's 13F filing for Q3 2026, filed 9 Oct 2026.